- Login to your account
- Free Membership to Digital Look
- Site Map
- Company A-Z
- Finance A-Z
- News Archive
- Events
Digital Look
- Company A-Z
- Company Search
- MarketStars Premium
- Portfolios & Watchlists
- Charting
- Screening Tools
- Visual Tools
- Mobile Tools / PDA
- Education Guides
- UK Shares
- Funds
- International Shares
- Bonds
- Currencies
- Commodities
- Covered Warrants
Moneyback on Petrol:
Market Cap
£20.19m
Change Today
-0.12p
Share Price
9.13p
ALIZYME AT THE 2008 BIO INTER
|
Immediate Release |
12 June 2008 |
ALIZYME TO PRESENT AT THE 2008 BIO International Convention
Cambridge UK, 12 June 2008: Alizyme plc (LSE: AZM) announces that Tim McCarthy, Chief Executive Officer, will be presenting at the 2008 BIO International Convention to be held at the San Diego Convention Center, San Diego, CA USA, 17-20 June, 2008. The presentation will be on Thursday, June 19, 2008 in Room 3 at 14.00 (PT) / 22.00 (BST).
For further information, please contact:
|
ALIZYME plc |
Tel No: + 44 (0) 1223 896000 |
|
Tim McCarthy, Chief Executive Officer David Campbell, Finance Director |
|
|
|
|
|
BUCHANAN COMMUNICATIONS |
Tel No: + 44 (0) 20 7466 5000 |
|
Lisa Baderoon Rebecca Skye Dietrich |
|
Further information on Alizyme can be found on the Company's website: www.alizyme.com
EDITOR'S NOTES
Alizyme is a speciality biopharmaceutical development company, based in Cambridge, UK, targeting the treatment and management of gastrointestinal disorders, obesity and diabetes. It has a portfolio of products which include: cetilistat (in pre-Phase III development for the treatment of obesity and diabetes), COLAL-PRED® (in Phase III development in Europe for the treatment of acute ulcerative colitis) and ATL-104 (successfully completed a Phase IIa trial for the treatment of mucositis).